Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
765 participants
OBSERVATIONAL
2019-01-12
2020-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic
NCT02708199
Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar
NCT02792816
Prevalence Survey of Antimalarial Drug Resistance Markers
NCT03217851
Malaria Genetic Surveillance
NCT03384498
Malaria Genetic Surveillance in Cambodia
NCT03384472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shwegyin
Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
Drug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
Pinlebu
Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
Drug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug resistance molecular markers
Proportion of the drug resistance molecular markers will be found-out and compared.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Migrant population (moving from their normal residence place and working at a new place such as forest related activities, gold-mines or plantation sites for more than 3 months- 3 years)
* Both sex
* Participant who give informed-consent to participate the study
Exclusion Criteria
* Patients with clinical symptoms of malaria at the time of examination
* Known history of malaria within 14 days
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Malaria Control Program, Myanmar
OTHER_GOV
Department of Medical Research, Lower Myanmar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myat Htut Nyunt
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Myat H Nyunt, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Myat Phone Kyaw
Yangon, , Burma
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMR_2018-108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.